🇺🇸 Peg-filgrastim in United States
28 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 23 April 2025 – 23 April 2026
- Total reports: 28
Most-reported reactions
- Death — 5 reports (17.86%)
- Febrile Neutropenia — 4 reports (14.29%)
- Neutropenia — 3 reports (10.71%)
- Oropharyngeal Pain — 3 reports (10.71%)
- Urticaria — 3 reports (10.71%)
- Disease Progression — 2 reports (7.14%)
- Drug Hypersensitivity — 2 reports (7.14%)
- Odynophagia — 2 reports (7.14%)
- Pyrexia — 2 reports (7.14%)
- Sepsis — 2 reports (7.14%)
Other Oncology approved in United States
Frequently asked questions
Is Peg-filgrastim approved in United States?
Peg-filgrastim does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Peg-filgrastim in United States?
Asan Medical Center is the originator. The local marketing authorisation holder may differ — check the official source linked above.